WO2004097017A3 - Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells - Google Patents

Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells Download PDF

Info

Publication number
WO2004097017A3
WO2004097017A3 PCT/US2004/013660 US2004013660W WO2004097017A3 WO 2004097017 A3 WO2004097017 A3 WO 2004097017A3 US 2004013660 W US2004013660 W US 2004013660W WO 2004097017 A3 WO2004097017 A3 WO 2004097017A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid analog
compositions
cells
enhancing transport
Prior art date
Application number
PCT/US2004/013660
Other languages
French (fr)
Other versions
WO2004097017A2 (en
Inventor
Patrick L Iversen
Hong M Moulton
Michelle H Nelson
Andrew D Kroeker
David A Stein
Original Assignee
Avi Biopharma Inc
Patrick L Iversen
Hong M Moulton
Michelle H Nelson
Andrew D Kroeker
David A Stein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc, Patrick L Iversen, Hong M Moulton, Michelle H Nelson, Andrew D Kroeker, David A Stein filed Critical Avi Biopharma Inc
Priority to DE602004028930T priority Critical patent/DE602004028930D1/en
Priority to AT04751183T priority patent/ATE479763T1/en
Priority to EP04751183A priority patent/EP1629105B1/en
Priority to CA2523672A priority patent/CA2523672C/en
Priority to AU2004235396A priority patent/AU2004235396B2/en
Publication of WO2004097017A2 publication Critical patent/WO2004097017A2/en
Publication of WO2004097017A3 publication Critical patent/WO2004097017A3/en
Priority to AU2011200720A priority patent/AU2011200720B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.
PCT/US2004/013660 2003-04-29 2004-04-29 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells WO2004097017A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE602004028930T DE602004028930D1 (en) 2003-04-29 2004-04-29 COMPOSITIONS FOR IMPROVING ANTISENSE EFFECTIVENESS AND TRANSPORT OF NUCLEIC ACID ANALOGUE IN CELLS
AT04751183T ATE479763T1 (en) 2003-04-29 2004-04-29 COMPOSITIONS FOR IMPROVING ANTISENSE EFFECTIVENESS AND TRANSPORT OF NUCLEIC ACID ANALOGUE INTO CELLS
EP04751183A EP1629105B1 (en) 2003-04-29 2004-04-29 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
CA2523672A CA2523672C (en) 2003-04-29 2004-04-29 Compositions for enhancing transport of molecules into cells
AU2004235396A AU2004235396B2 (en) 2003-04-29 2004-04-29 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
AU2011200720A AU2011200720B2 (en) 2003-04-29 2011-02-18 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46670303P 2003-04-29 2003-04-29
US60/466,703 2003-04-29

Publications (2)

Publication Number Publication Date
WO2004097017A2 WO2004097017A2 (en) 2004-11-11
WO2004097017A3 true WO2004097017A3 (en) 2005-04-07

Family

ID=33418412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013660 WO2004097017A2 (en) 2003-04-29 2004-04-29 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells

Country Status (9)

Country Link
US (4) US7468418B2 (en)
EP (2) EP1629105B1 (en)
AT (1) ATE479763T1 (en)
AU (2) AU2004235396B2 (en)
CA (1) CA2523672C (en)
DE (1) DE602004028930D1 (en)
DK (1) DK2351844T3 (en)
ES (2) ES2500921T3 (en)
WO (1) WO2004097017A2 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
ES2500921T3 (en) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Compositions to enhance the transport and antisense efficacy of nucleic acid analogs in cells
US20050203041A1 (en) * 2003-09-23 2005-09-15 Mourich Dan V. Antisense compound and method for selectively killing activated T cells
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
US20050234002A1 (en) * 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
SI2206781T1 (en) 2004-06-28 2016-05-31 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
PT1766012E (en) 2004-07-02 2011-09-05 Avi Biopharma Inc Antisense antibacterial method and compound
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
US20100256041A1 (en) * 2004-11-12 2010-10-07 Christophe Bonny Conjugate Molecule Compounds With Enhanced Cell Uptake Activity
EP1855694B1 (en) * 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
AU2006267051B2 (en) * 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
CA2621964A1 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
EP2109363A4 (en) * 2006-12-29 2014-07-09 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
JP5864100B2 (en) * 2007-06-29 2016-02-17 サレプタ セラピューティクス インコーポレイテッド Tissue-specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US7989608B2 (en) * 2007-12-28 2011-08-02 Avi Biopharma Inc. Immunomodulatory agents and methods of use
EP2119783A1 (en) * 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010048586A1 (en) 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010099510A2 (en) * 2009-02-27 2010-09-02 The Administrators Of The Tulane Educational Fund Amino acid-based compounds, their methods of use, and methods of screening
WO2010120262A1 (en) * 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
WO2010121125A1 (en) 2009-04-17 2010-10-21 Wake Forest University Health Sciences Il-13 receptor binding peptides
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
KR102487132B1 (en) 2009-11-12 2023-01-10 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
CN102712928B (en) 2009-11-13 2017-08-04 萨雷普塔治疗公司 Antisense antiviral compound and the method for treating influenza infection
US20120309684A1 (en) * 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds
JP5457813B2 (en) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 ADPLL circuit, semiconductor device and portable information device
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
US9068185B2 (en) * 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
ES2816898T3 (en) 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compounds that modulate the signaling activity of interleukins 17 and 23
KR102095478B1 (en) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2834128A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013033407A2 (en) 2011-08-30 2013-03-07 The Regents Of The University Of California Identification of small molecules that enhance therapeutic exon skipping
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2780299A4 (en) 2011-11-18 2015-04-22 Sarepta Therapeutics Inc Functionally-modified oligonucleotides and subunits thereof
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
JP6542662B2 (en) 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド Boronic acid conjugates of oligonucleotide analogs
WO2014011177A1 (en) * 2012-07-12 2014-01-16 Smith Holdings, Llc Antisense p53 phosphorodiamidate morpholino composititons, methods and indications
BR122020016865B1 (en) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. ANTISENSE OLIGONUCLEOTIDE, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE OF SAID COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD)
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
US9885040B2 (en) * 2013-04-12 2018-02-06 The Curators Of The University Of Missouri SMN2 element 1 antisense compositions and methods and uses thereof
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN105307670A (en) 2013-06-26 2016-02-03 埃克西金炎症有限公司 New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
CA2949104C (en) 2014-05-23 2023-09-26 Genzyme Corporation Multiple oligonucleotide moieties on peptide carrier
JP6994941B2 (en) 2014-12-31 2022-02-04 オレゴン ステート ユニバーシティ Antisense antibacterial compounds and methods
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3858993A1 (en) * 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2017112888A1 (en) 2015-12-23 2017-06-29 David Greenberg Antisense antibacterial compounds and methods
SG11201808964PA (en) 2016-04-18 2018-11-29 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
NZ747685A (en) 2016-04-29 2023-05-26 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
BR112019012664A2 (en) 2016-12-19 2020-01-21 Sarepta Therapeutics Inc exon jump oligomer conjugates for muscular dystrophy
MD3554553T2 (en) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
CN206351680U (en) * 2017-01-04 2017-07-25 上海蔚来汽车有限公司 Self-adapting adjusted positions plus Unlocking clamp
TW201919682A (en) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 Novel compounds activating the Nrf2 pathway
JP7441455B2 (en) 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
US20200254002A1 (en) 2017-09-28 2020-08-13 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536060A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド Combination therapy to treat muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
CA3122200A1 (en) * 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
EA202191601A1 (en) 2018-12-13 2022-01-19 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXON SKIP IN MUSCULAR DYSTROPHY
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
WO2021042039A1 (en) * 2019-08-29 2021-03-04 Ajk Pharmaceutical Llc Synthetic antimicrobial peptides
US20230020092A1 (en) * 2019-12-19 2023-01-19 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
EP4267191A1 (en) 2020-12-23 2023-11-01 Sarepta Therapeutics, Inc. Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
EP4330395A1 (en) 2021-04-30 2024-03-06 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062297A1 (en) * 2000-02-14 2001-08-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across biological membranes and tissues
WO2003068942A2 (en) * 2002-02-13 2003-08-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
DE3687030T2 (en) 1985-03-15 1993-03-11 James Summerton STEREO-REGULAR POLYNUCLEOTID-BINDING POLYMERS.
US5525465A (en) * 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5378841A (en) 1989-12-20 1995-01-03 Antivirals Inc. Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
CA2063529A1 (en) 1991-03-22 1992-09-23 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
DE656950T1 (en) 1992-08-21 1996-03-14 Biogen Inc TAT DERIVATE TRANSPORT POLYPEPTIDE.
KR100316205B1 (en) * 1993-01-07 2002-04-24 아브람 엠. 골드핑거 Antisense Inhibition of c-myc to Regulate Smooth Muscle Cell Proliferation
GB9318288D0 (en) 1993-09-03 1993-10-20 Nycomed Imaging As Improvements in or relating to contrast agents
WO1995007072A2 (en) 1993-09-09 1995-03-16 Schering Aktiengesellschaft Active principles and gas containing microparticles
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5648098A (en) 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
CN1263473A (en) 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 Composition and method for enhancing transport across biological membranes
WO1999005302A1 (en) 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
CA2337361C (en) 1998-07-13 2010-11-16 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
EP1109821A4 (en) * 1998-08-25 2002-04-03 Human Genome Sciences Inc 49 human secreted proteins
JP2002535015A (en) 1999-01-29 2002-10-22 エイブイアイ バイオファーマ， インコーポレイテッド Non-invasive method for detecting target RNA
EP1173614A4 (en) * 1999-04-08 2003-10-29 Oasis Biosciences Inc Antisense oligonucleotides comprising universal and/or degenerate bases
DE60039601D1 (en) 1999-05-24 2008-09-04 Avi Biopharma Inc ANTISENSE AGAINST C-MYC FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE
US6303573B1 (en) * 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
MXPA02001857A (en) * 1999-08-24 2003-07-14 Cellgate Inc Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties.
CA2386192A1 (en) 1999-10-07 2001-04-12 Avi Biopharma, Inc. C-myc antisense-treated hematopoietic stem cell composition and method
ATE393221T1 (en) 1999-11-29 2008-05-15 Avi Biopharma Inc UNCHARGED ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST BACTERIAL 16S AND 23S RRNAS AND USES THEREOF
US7049431B2 (en) 2000-01-04 2006-05-23 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US6559279B1 (en) * 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
AU2002225714A1 (en) 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
EP1364201A4 (en) * 2001-02-06 2005-01-05 Univ Auburn Ligand sensor devices and uses thereof
US20030031655A1 (en) * 2001-02-08 2003-02-13 Sequitur, Inc. Methods of light activated release of ligands from endosomes
JP2005508832A (en) * 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド Transporter with arginine part at intervals
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
EP1399462A4 (en) * 2001-05-17 2008-03-05 Avi Biopharma Inc Combined approach to treatment of cancer using a c-myc antisense oligomer
AT413185B (en) 2001-05-17 2005-12-15 Blum Gmbh Julius FURNITURE DRAWER
JP3735292B2 (en) * 2001-07-26 2006-01-18 三菱重工業株式会社 Dietary health foods and formulations
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
MXPA04005611A (en) * 2001-12-11 2005-04-19 Cellgate Inc Guanidinium transport reagents and conjugates.
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
ES2500921T3 (en) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Compositions to enhance the transport and antisense efficacy of nucleic acid analogs in cells
KR100835786B1 (en) 2003-07-08 2008-06-09 제넨테크, 인크. - il-17a/f heterologous polypeptides and therapeutic uses thereof
EP2251352A1 (en) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050203041A1 (en) 2003-09-23 2005-09-15 Mourich Dan V. Antisense compound and method for selectively killing activated T cells
US7786151B2 (en) * 2004-01-09 2010-08-31 Kinopharma, Inc. Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
US20050234002A1 (en) * 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
WO2005077333A2 (en) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Gel-based delivery of recombinant adeno-associated virus vectors
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
MXPA06012605A (en) 2004-05-04 2006-12-15 Nastech Pharm Co Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells.
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2005117992A2 (en) * 2004-05-30 2005-12-15 Cemines, Inc. Controlled delivery of therapeutic compounds
SI2206781T1 (en) 2004-06-28 2016-05-31 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1789553B1 (en) * 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
EP2801366A3 (en) * 2004-09-02 2015-04-29 Cognosci, Inc. Improved apo E analogs and methods for their use
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1855694B1 (en) * 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
RU2007129263A (en) 2005-02-14 2009-03-20 Вайет (Us) ANTIBODIES TO INTERLEUKIN-17F AND OTHER IL-17F MEDIA-BASED ANTAGONISTS SIGNAL TRANSMISSION AND THEIR APPLICATION
CA2605931A1 (en) * 2005-04-26 2006-11-02 Karyon-Ctt Ltd Diagnostic and therapeutic agents
WO2008005002A1 (en) 2006-06-30 2008-01-10 Oligos Ets. Inc. Compositions and methods for the treatment of muscle wasting
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
CA2621964A1 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
EP1954836B1 (en) 2005-11-08 2014-01-08 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
WO2007103529A2 (en) 2006-03-07 2007-09-13 Avi Biopharma, Inc. Antisense antiviral compound and method for treating arenavirus infection
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
EP2735568B8 (en) * 2006-05-10 2017-09-27 Sarepta Therapeutics, Inc. Oligonucleotide analogs having cationic intersubunit linkages
WO2008018795A1 (en) * 2006-08-11 2008-02-14 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
AU2007297535C1 (en) * 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
FR2908999B1 (en) * 2006-11-29 2012-04-27 Biomerieux Sa NOVEL DRUG FOR THE INHIBITION, PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS.
EP1938802A1 (en) 2006-12-22 2008-07-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Interfering RNAs targeting pro-inflammatory cytokines
JP5864100B2 (en) * 2007-06-29 2016-02-17 サレプタ セラピューティクス インコーポレイテッド Tissue-specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
US20110039785A1 (en) 2007-12-20 2011-02-17 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
US7989608B2 (en) * 2007-12-28 2011-08-02 Avi Biopharma Inc. Immunomodulatory agents and methods of use
WO2009144481A2 (en) 2008-05-30 2009-12-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2010048586A1 (en) 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010101663A2 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Of New York University Live attenuated influenza virus vaccines comprising microrna response elements
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011049603A1 (en) 2009-10-22 2011-04-28 Dana-Farber Cancer Institute, Inc. Biomarkers to identify hiv-specific t-cell subsets
CN102712928B (en) 2009-11-13 2017-08-04 萨雷普塔治疗公司 Antisense antiviral compound and the method for treating influenza infection
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
ES2816898T3 (en) * 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compounds that modulate the signaling activity of interleukins 17 and 23
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062297A1 (en) * 2000-02-14 2001-08-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across biological membranes and tissues
WO2003068942A2 (en) * 2002-02-13 2003-08-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN CHANG-PO ET AL: "A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide.", BIOCONJUGATE CHEMISTRY. 2003 MAY-JUN, vol. 14, no. 3, May 2003 (2003-05-01), pages 532 - 538, XP002314110, ISSN: 1043-1802 *
ERIKSSON MAGDALENA ET AL: "Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) into Escherichia coli.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 1 MAR 2002, vol. 277, no. 9, 1 March 2002 (2002-03-01), pages 7144 - 7147, XP002314499, ISSN: 0021-9258 *
GHOSH C ET AL: "INTRACELLULAR DELIVERY STRATEGIES FOR ANTISENSE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 10, no. 4, August 2000 (2000-08-01), pages 263 - 274, XP001147441, ISSN: 1087-2906 *
IVERSEN P L: "Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.", CURRENT OPINION IN MOLECULAR THERAPEUTICS. JUN 2001, vol. 3, no. 3, June 2001 (2001-06-01), pages 235 - 238, XP009042729, ISSN: 1464-8431 *
MOULTON HONG M ET AL: "HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers.", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT. FEB 2003, vol. 13, no. 1, February 2003 (2003-02-01), pages 31 - 43, XP009042731, ISSN: 1087-2906 *
RICHARD JEAN PHILIPPE ET AL: "Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 3 JAN 2003, vol. 278, no. 1, 3 January 2003 (2003-01-03), pages 585 - 590, XP002314498, ISSN: 0021-9258 *
ZUBIN E M ET AL: "Oligonucleotide-peptide conjugates as potential antisense agents", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 456, no. 1, 30 July 1999 (1999-07-30), pages 59 - 62, XP004260038, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
AU2011200720B2 (en) 2012-11-08
US9572899B2 (en) 2017-02-21
US20090082547A1 (en) 2009-03-26
ES2351976T3 (en) 2011-02-14
EP2351844B1 (en) 2014-06-11
DK2351844T3 (en) 2014-09-22
US7468418B2 (en) 2008-12-23
WO2004097017A2 (en) 2004-11-11
CA2523672C (en) 2012-07-17
US10300149B2 (en) 2019-05-28
ES2500921T3 (en) 2014-10-01
US20200016280A1 (en) 2020-01-16
US20170368203A1 (en) 2017-12-28
AU2004235396A1 (en) 2004-11-11
AU2004235396B2 (en) 2010-11-25
ATE479763T1 (en) 2010-09-15
US20040265879A1 (en) 2004-12-30
CA2523672A1 (en) 2004-11-11
AU2011200720A1 (en) 2011-03-10
DE602004028930D1 (en) 2010-10-14
EP1629105A2 (en) 2006-03-01
EP2351844A1 (en) 2011-08-03
US10905782B2 (en) 2021-02-02
EP1629105B1 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
WO2004097017A3 (en) Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
Stetsenko et al. Efficient conjugation of peptides to oligonucleotides by “native ligation”
RU2582235C2 (en) Low-molecular conjugates for intracellular delivery of nucleic acids
JP6997177B2 (en) SCN9A antisense oligonucleotide
de la Torre et al. Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences
EP3610884A1 (en) Peptide containing conjugates for dual molecular delivery of oligonucleotides
WO2001004135A3 (en) Crosslinked dna condensate compositions and gene delivery methods
MX2009002856A (en) Polymeric conjugates containing positively-charged moieties.
EP4272748A3 (en) Antisense oligonucleotides for inducing exon skipping and methods of use thereof
ATE195144T1 (en) NEW PROTEIN POLYCATION CONJUGATES
CA2498772A1 (en) Modified pna molecules
CA2382521A1 (en) Oligonucleotide n3'.fwdarw.p5' thiophosphoramidates: their synthesis and use
DE50006269D1 (en) COMBINATIONS FOR THE INTRODUCTION OF NUCLEIC ACIDS IN CELLS
IL163667A (en) Conjugates comprising controlled substances covalently bound to peptides or amino acids and compositions comprising same
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2001094547A3 (en) Molecular delivery vehicle for delivery of selected compounds to targets
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
Ohmori et al. Importance of hydrophobic region in amphiphilic structures of α-helical peptides for their gene transfer-ability into cells
CA2352286A1 (en) Intracellular targeted delivery of compounds by 70 kd heat shock protein
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
WO2003057164A3 (en) Compounds for delivering substances into cells
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO2000043043B1 (en) Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
Schmidt et al. Monofunctionally trans‐Diammine Platinum (ii)‐Modified Peptide Nucleic Acid Oligomers: A New Generation of Potential Antisense Drugs
AU2009208646A1 (en) Cationic siRNAs, synthesis and use for interfering RNA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004235396

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2523672

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004235396

Country of ref document: AU

Date of ref document: 20040429

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004235396

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004751183

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004751183

Country of ref document: EP